IGF-I in the clinics: Use in retinopathy of prematurity

Ann Hellström, David Ley, Ingrid Hansen-Pupp, Boubou Hallberg, Luca A Ramenghi, Chatarina Löfqvist, Lois E H Smith, Anna Lena Hård

Research output: Contribution to journalArticle

Abstract

Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalGrowth Hormone and IGF Research
Volume30-31
DOIs
Publication statusPublished - Oct 11 2016

Keywords

  • Review
  • Journal Article

Fingerprint Dive into the research topics of 'IGF-I in the clinics: Use in retinopathy of prematurity'. Together they form a unique fingerprint.

  • Cite this

    Hellström, A., Ley, D., Hansen-Pupp, I., Hallberg, B., Ramenghi, L. A., Löfqvist, C., Smith, L. E. H., & Hård, A. L. (2016). IGF-I in the clinics: Use in retinopathy of prematurity. Growth Hormone and IGF Research, 30-31, 75-80. https://doi.org/10.1016/j.ghir.2016.09.005